Avidity biosciences reports second quarter 2025 financial results and recent highlights

Aligned with fda on del-brax accelerated and full approval pathways for fshd, reported positive topline data from phase 1/2 fortitude™ trial, and initiated global confirmatory phase 3 study planned del-zota bla submission at year end 2025 for dmd44 on track to be avidity's first bla submission on track for three potential bla submissions over a 12-month period strong balance sheet and cash runway to mid-2027 enabling global commercial launch readiness; first potential commercial launch in u.s. in 2026  san diego , aug. 7, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™) to profoundly improve people's lives, today reported financial results for the second quarter ended june 30, 2025 and highlighted recent progress. "avidity continues to deliver on its leadership in rna therapeutics as we prepare for three potential bla submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution," said sarah boyce, president and chief executive officer of avidity.
RNA Ratings Summary
RNA Quant Ranking